Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
gilead sciences
7
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
7
×
startups
7
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alzheimer's disease
boston top stories
deals
cancer immunotherapy
europe blog main
europe top stories
merck
novartis
abbvie
astrazeneca
biogen
cancer
What
bio
roundup
7
×
acquisitions
ceo
drug
pfizer’s
amid
biggest
bombast
cancer
caught
coronavirus
covid
daniel
debate
develop
discussion
efforts
gilead
ipo
medicines
meso’s
miss
new
o’day
pandemic
presidential
promise
response
sciences
tuesday’s
vaccine
viewers
activity
albert
announced
approval
approvals
biogen
biogen’s
Language
unset
unknown
Current search:
roundup
×
" gilead sciences "
×
" seattle top stories "
×
startups
×
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More